Author | Mojtaba Akhtari, MD


Thrombocytopenia: Optimizing Approaches in Cancer Patients

April 15, 2015

Chemotherapy-induced thrombocytopenia causes nearly two-thirds of cases of thrombocytopenia in the cancer setting. In patients receiving chemotherapy, thrombocytopenia leads to dose reductions in 15% of treatment cycles and chemotherapy delays in 6% of cycles.

The Golden Era of Genomics and Management of Acute Myeloid Leukemia

April 12, 2012

Cancer treatment is undergoing significant developments and entering the new golden era of genomics which has true potentials for the promise of personalized medicine. Large-scale sequencing is changing our understanding of malignant disorders particularly acute myeloid leukemia.

Outcomes of Patients With MDS After Secondary Failure of Hypomethylating Drugs

December 03, 2011

Two recent reports show that the prognosis of MDS patients after secondary failure of hypomethylating drugs is poor, and switching from one failing hypomethylating drug to another cannot induce clinically significant responses.

It Is Better to Do RIC Without ATG

October 24, 2011

ATG is associated with reduced risk of acute and chronic graft-versus-host disease without increasing the risk of relapse in myeloablative donor transplants. However, there has been an ongoing debate about the role of ATG in reduced intensity conditioning (RIC) HSCT, and there are still bone marrow transplant centers that use ATG in the RIC setting, and their main argument is that ATG could help with engraftment and reducing the risk of GVHD. Different types and doses of ATG have been used in the RIC setting.